Efficacy and safety of Pioglitazone for treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.
Efficacy and safety of Pioglitazone for treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials. J Dermatolog Treat. 2019 May 22;:1-17 Authors: Chang G, Wang J, Song J, Zhang Z, Zhang L Abstract Background A growing number of studies have shown that thiazolidinedoniones(TZD) can be antipsoriatic. Pioglitazone is a representative of the class of antidiabetic drugs known as TZD. TZD can activate nuclear peroxisome proliferator-activated receptors (PPAR)-c. PPARs are expressed on epidermal keratinocytes and exert their effects by promoting the terminal differentiation of keratinocytes, inhibiting epidermal growth, and reducing inflammatory responses. These observations suggest that TZD have potential benefits in the treatment of cutaneous and metabolic pathologies associated with psoriasis. Objective A systematic review and meta-analysis was carried out to evaluate the efficacy of combined Pioglitazone treatment. We point out 3 controversial side effects from administration of Pioglitazone in psoriasis: elevated liver enzymes, weight gain, and nausea. Study selection Randomized, single blind, or double blind, published studies of Pioglitazone compared with placebo, given to patients with plaque psoriasis for 10 weeks or 12 weeks were considered for inclusion in this review. The primary outcomes were 75% or greater improvement in the Psoriasis Area and Severity Index score from baseline (PASI 75) with pioglitazone....
CONCLUSIONS: In morphea, pemphigus and psoriasis patients, the DLQI-R scoring improves the discriminatory power of the questionnaire by benefiting from the additional information in NRRs. The DLQI-R scoring may be useful both in clinical practice and research. A scoring chart has been developed to aid physicians with scoring. PMID: 31419310 [PubMed - as supplied by publisher]
Psoriasis is a frequent systemic inflammatory autoimmune disease characterized primarily by skin lesions with massive infiltration of leukocytes but frequently also presents with cardiovascular comorbidities. Especially polymorphonuclear neutrophils (PMNs) abundantly infiltrate psoriatic skin but the cues that prompt PMNs to home to the skin are not well defined. To identify PMN surface receptors that may explain PMN skin homing in psoriasis patients, we screened 332 surface antigens on primary human blood PMNs from healthy donors and psoriasis patients. We identified platelet surface antigens as a defining feature of psor...
Psoriasis severity categories have been important tools for clinicians to use in treatment decisions as well as to determine eligibility criteria for clinical studies. However, due to the heterogeneity of severity classifications and their lack of consideration for the impact of psoriasis involvement of special areas or past treatment history, patients may be mis-categorized, which can lead to under-treatment of psoriasis.
New system could flag a patient ’s learning disability to clinicians Related items fromOnMedica Too many CCGs ’ residential mental health placements are out-of-area Experts urge radical action on mental health crises Psoriasis patients need psychological care Mental and physical healthcare should be integrated CCGs ’ duties for children with disabilities
Yunlei Pan, Shunli Tang, Lina Xu, Siting Zheng, Jianjun Qiao, Hong FangIndian Journal of Dermatology, Venereology, and Leprology 2019 85(5):534-536
Soo Ick Cho, Suhwan Shin, Hanjae Lee, Seong Jin JoIndian Journal of Dermatology, Venereology, and Leprology 2019 85(5):536-538
Conclusion: The inflammatory process in psoriasis is orchestrated through chemokines. MIG is a potential serum biomarker for assessing disease severity.
Condition: Psoriasis Intervention: Device: transcutaneous electrical nerve stimulation (TENS) unit Sponsor: Wake Forest University Health Sciences Not yet recruiting